Background: The objective of this comparative neuropathologic study was to determine the extent to which dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) are distinct entities or part of a continuum with respect to the duration of parkinsonism. Methods: We evaluated the relationship between cortical ␣-synuclein pathology, plaques (Consortium to Establish a Registry for Alzheimer's Disease [CERAD]), tangles (Braak staging), and cholinergic deficits (choline acetyltransferase in temporal cortex) in 57 prospectively assessed patients (29 DLB, 28 PDD), confirmed at autopsy. The PDD group was divided according to the median duration of parkinsonism prior to dementia. Results: There was an association between longer duration of parkinsonism prior to dementia and less severe cortical ␣-synuclein pathology ( 2 10.4, df 2, p ϭ 0.006) and lower CERAD plaque scores ( 2 26.6, df 9, p ϭ 0.002), but not Braak staging. These findings were confirmed in a further correlation analysis, which also identified an unexpected correlation between more pronounced cortical cholinergic deficits and longer duration of parkinsonism prior to dementia (R ϭ Ϫ0.37, p ϭ 0.04). Conclusion: While there is a clear relationship between the duration of Parkinson disease prior to the onset of dementia and key neuropathologic and neurochemical characteristics, there is a gradation of these differences across the dementia with Lewy bodies/Parkinson disease dementia spectrum and the findings do not support an arbitrary cut-off between the two disorders.
An arbitrary but generally accepted distinction has been made in current International Consensus diagnostic criteria between patients presenting with parkinsonism prior to the onset of dementia (Parkinson disease dementia, PDD) and developing parkinsonism and dementia concurrently (dementia with Lewy bodies, DLB). [1] [2] [3] The diagnostic conceptualization of these syndromes, understanding the relationship between the duration of PD prior to dementia and distribution of pathologic and neurochemical disease substrates, is essential to inform clinical practice, design of clinical trials, and development of new treatments.
There are few neuropathologic studies directly comparing the two conditions, [1] [2] [3] [4] and many focusing on PD have not clearly distinguished between patients with and without dementia. In PD, the Lewy bodies are mainly located in the substantia nigra and other brainstem nuclei such as the locus ceruleus and raphe 5 whereas Lewy bodies are present in both the brainstem and a number of neocortical and archicortical ar-eas in DLB. 6, 7 In PD there are nigrostriatal dopaminergic deficits 8 and also neocortical cholinergic deficits, particularly in patients with dementia. 9 Neuropathologic studies focusing upon PDD indicate that diffuse cortical Lewy bodies are the main substrate of dementia in these patients. 6, 10 Nevertheless, concurrent senile plaques and neurofibrillary tangles are common in both PDD and DLB, although usually insufficient to meet the NIA Reagan diagnostic criteria for AD. 6, 10 The few studies directly comparing PDD and DLB have based the distinction between conditions on the 1-year rule described in the McKeith 1 criteria, where patients presenting with less than 1 year of parkinsonism prior to dementia are diagnosed with DLB and patients with a longer duration of parkinsonism before the onset of dementia are diagnosed with PDD. Using this definition, some preliminary reports have suggested that patients with DLB have significantly greater cortical Lewy body pathology 11, 12 and more pronounced atrophy 13 than those with PDD. In contrast, a recent study did not identify any significant differences in cortical Lewy body or Alzheimer type pathology between the two conditions, 6 although the number of patients with PDD was small. A more comprehensive and larger study confirmed higher densities of Lewy bodies and senile plaques in DLB vs PDD, and reported that widespread neurofibrillary tangles were rare in both disorders. 14 Nevertheless, these finding were similar to an earlier (pre ␣-synuclein) report 15 comparing Alzheimer type pathology and Lewy body density in PD, PDD, and DLB. Even fewer reports have directly compared neurochemical changes in DLB and PDD, with initial studies suggesting severe cholinergic deficits in both conditions. 9, 16 Methods. Recruitment procedure and diagnosis. The clinical and autopsy aspects of the study were fully approved by Human Subjects Research Ethics Committees in each of the centers. We studied 57 autopsy-confirmed DLB, or PDD, patients who participated in the Newcastle upon Tyne, UK, dementia Case Register series or the Stavanger community PD cohort. All subjects received prospective, standardized, annual clinical evaluations during life, including clinical histories, cognitive and motor evaluations. DLB was diagnosed clinically and neuropathologically according to consensus criteria, 1 and PD was diagnosed according to established clinical 17, 18 and neuropathologic 5 criteria.
As the purpose of the current study is to avoid such assumptions, we use the term Lewy body dementias to encompass DLB and PDD.
Clinical assessment. The assessment battery incorporated successive cognitive evaluations which included the Mini-Mental State Examination and longitudinal assessment of parkinsonism, rated using Unified PD Rating Scale 19 and staged with the Hoehn & Yahr scale. 20 In the PD group, a diagnosis of dementia according to the Diagnostic and Statistical Manual of Mental Disorders-III-R was based on a semi-structured interview with the patient and a caregiver, and standardized cognitive rating scales (further information on the cognitive assessment and diagnosis of dementia in PD provided in reference 2).
Neuropathologic assessment. All neuropathologic evaluations were completed at Newcastle, blind to clinical assignment. The severity of plaques was assessed using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) guidelines. 21 Braak and Braak staging was performed to stage tangle pathology 22 using AT8 immunohistochemistry (IHC) and the Gallyas silver stain. Lewy bodies were stained with a monoclonal alpha synuclein antibody from Novocastra Laboratories (ASYN). Standard indirect IHC was performed, using Vectastain Elite ABC kit and monoclonal ASYN (1:30 dilution), for 1 hour at room temperature, followed by secondary mouse antibody visualization with DAB solution and counterstaining with hematoxylin. Antigen retrieval was carried out using paraffin embedded tissue (microtome 10 m sections mounted on 3-aminopropyl triethoxysilane [APES] coated glass slides) and immersed in EDTA tetrasodium dihydrate solution, in a pressure cooker at 100°C for 5 minutes. Lewy bodies were assessed in brainstem, limbic, and neocortical areas using the principles outlined in the DLB consensus criteria, with a modified rating system utilizing ␣-synuclein staining and a 0-20 semiquantified scale following the same hierarchy as the system within the DLB consensus criteria but incorporating additional rating points within the neocortical range. 1, 2, 23 This was undertaken as the original scoring system was based on ubiquitin IHC and greater sensitivity is needed to avoid ceiling effects with ␣-synuclein staining. The scoring from 0 to 10 reflects brainstem and limbic cortex pathology, and scores from 11 to 20 provide a semi-quantitative measure, with a particular emphasis on neocortical pathology (scoring system shown in table 1). Scoring was based on the presence of intraneuronal LB (although Lewy neurites were not specifically used in the scoring system, they were noted to correlate with the LB density).
Neurochemical assessment. Snap frozen blocks of tissue, maintained at Ϫ70°C from the temporal cortex (BA 36), were subdissected to remove representative samples of gray matter. Choline acetyltransferase (ChAT) was measured biochemically in tissue homogenates using a modification of the original radiochemical method of Fonnum, based on synthesis of 14Cacetylcholine from 14C-acetylcoenzyme A, and expressing enzyme activities in terms of unit protein. 18 Statistical evaluations. To enable evaluation of the neuropathologic, neurochemical, and clinical characteristics of participants across the Lewy body dementia spectrum, the PDD patients were split by median duration of PD prior to dementia (9.5 years) creating three groups: DLB, PDD Ͻ 9.5 years of parkinsonism prior to dementia, PDD Ͼ 9.5 years of parkinsonism prior to dementia. Group comparisons were made using the 2 or Kruskal-Wallis test, as appropriate. In addition, the overall relationship between the duration of PD prior to dementia and the specific neuropathologic and neurochemical measures were evaluated using the Spearman's R. The evaluation of the rate of cognitive decline was undertaken using the onset of dementia as the baseline value. All statistics used the SPSS computerized package with a p value Ͻ 0.05 to indicate significance.
Results.
We studied 57 patients with DLB or PDD with complete neuropathologic evaluation (mean age at death 76.2 SD 5.7 years, years of dementia 2.9 SD 2.2: mean MMSE closest to death 12.2 SD 9.2, 57% female; frozen tissue available for 31 patients).
The onset of dementia varied from 9 years prior to parkinsonism in the patients with DLB to 25.5 years after the onset of parkinsonism in the patients with PDD, with median duration of parkinsonism prior to dementia of 9.5 years in those with PDD. The pathologic characteristics of the three groups are shown in table 2 (splitting the PDD group by the median duration of PD prior to dementia). There was an association between a longer duration of parkinsonism prior to dementia and less severe cortical ␣-synuclein pathology ( 2 10.4, df 2, p ϭ 0.006) and lower CERAD plaque scores ( 2 26.6, df 9, p ϭ 0.002), but no difference in Braak staging. Of particular note, there are three times as many patients with DLB (66%) as patients with PD with long duration of parkinsonism prior to dementia (21%) with abundant plaques. The patients with PD with short duration of parkinsonism prior to dementia are more likely to have moderate-type density (43%) with abundant plaques in 14% (table 2) . A further evaluation correlating the number of years of parkinsonism prior to dementia with the key neuropathologic characteristics con- firmed the relationship between the increasing duration of parkinsonism prior to dementia and reduced severity of plaques (CERAD score -R ϭ Ϫ0.54, p Ͻ 0.0001) and also ␣-synuclein pathology (R ϭ Ϫ0.26, p ϭ 0.047). In addition, there was a correlation between longer duration of parkinsonism prior to dementia and lower ChAT (BA36) (R ϭ Ϫ0.37, p ϭ 0.04), but no relationship with Braak staging (R ϭ 0.05, p ϭ 0.73). The clinical characteristics are shown in table 3. The only significant difference among the three groups was an association between Hoehn and Yahr stage closest to death and the duration of PD prior to dementia.
Discussion. In this relatively large cohort of prospectively studied, autopsy-confirmed patients with DLB and PDD, we demonstrate a correlation between the duration of parkinsonism prior to dementia and the severity of plaques, cortical ␣-synuclein pathology, and severity of cortical cholinergic deficits. No relationship was seen with the severity of tangles. Some of the subgroups are modest in size, but there is a gradation of change across the groups and the changes in the pathologic and neurochemical characteristics are associated with the duration of PD prior to dementia in a correlation analysis, suggesting that the findings are robust. Although there are clear differences between patients with DLB at one end of the spectrum and people with more than 10 years of PD prior to dementia at the other, the data do not suggest that any specific cut-off threshold based upon the relationship between the onset of dementia and the onset of PD would help distinguish distinct and meaningful biologic entities.
As the majority of previous research has focused on the distinction between DLB and PDD, the underlying pathology and neurochemistry in patients with longstanding parkinsonism prior to dementia has received little consideration. The current study indicates that these individuals differ in important ways from patients with DLB, with a threefold reduction in the frequency of abundant plaques and 20% less cortical ␣-synuclein pathology, but 30% greater loss of ChAT. The presence of increased beta amyloid in the early PD dementia group may reflect the induction of beta amyloidosis by ␣-synuclein pathology in the cortex. Abeta-40 plaque levels are greater in AD cases with secondary ␣-synuclein aggregates. 24 Although the key disease substrates are the same across the spectrum of DLB and PDD, the different severity of cortical pathologic lesions and neurochemical deficits, particularly the more severe cortical ␣-synuclein pathology in patients with a shorter duration of PD prior to dementia, strongly suggests a different pathologic pattern of disease evolution at the extremes of the continuum, consistent with previous studies identifying a significant association between the duration of PD and neuronal loss in the substantia nigra in PDD but not DLB. 4 The Braak model of PD 25 suggests that the LB pathology begins in selected brainstem nuclei and then advances in a predictable manner, involving limbic structures, and subsequently reaches the neocortex. However, the early presentation of dementia with later occurring parkinsonism in DLB suggests that the site of the initial lesions differs in the two syndromes. In DLB, preliminary studies indicate that the Lewy pathology starts in the amygdala, advances to the limbic cortex, and finally to the neocortex. 26 However, nonuniformity in the regional pattern of Lewy pathology has been reported 27 indicating that the most vulnerable neurons may differ between different patients with Lewy body disease, a hypothesis which receives strong support from our study. The finding that neocortical cholinergic deficits are more extensive with increasing duration of PD prior to dementia is an important but unexpected finding, particularly in the context of less severe cortical pathology, and it is likely that the cholinergic loss is mediated by different factors in patients with longstanding PD. Progressive nigral degeneration may result in degeneration of the nucleus basalis of Meynert (nbM) which depends on dopaminergic and to a lesser extent other aminergic input for trophic maintenance. 28 In addition, in the marmoset many cholinergic neurones in the nbM contain tyrosine hydroxylase, suggesting that both acetylcholine and catecholamines may be synthesized as colocalized neurotransmitters within the same magnocellular neurones. 29 Thus the same etiologic factors resulting in dopaminergic neuron loss may affect cholinergic populations.
A key related clinical question is whether the response to cholinergic therapies is likely to vary across the PDD/DLB continuum. From the current data, it is clear that cortical cholinergic deficits are prominent across the full spectrum, although a preferential response to cholinesterase therapy may be expected in patients with PDD with a longer duration of PD prior to dementia, given the greater severity of cholinergic deficits in these patients.
